Simultaneous blockade of lymphocyte activation gene-3 (LAG-3) and programmed-death-1 (PD-1) pathways enhance anti-tumor activity in patients with melanoma. It is not known if this immunotherapy induces unique immune modulation or how this may relate to clinical outcomes, compared to the single modalities. We conducted a randomized three-arm phase 2 trial (NCT03743766) in advanced melanoma comparing lead-in treatment with one cycle…
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma
medRxiv Oncology | | Karapetyan, L., Cillo, A. R., Wang, S., Karunamurthy, A., Massa, R. C., Rohatgi, A., Deitrick, C., Najjar, Y. G., Davar, D., Luke, J. J., Sander, C., Kunning, S. R., Rose, A., Bradley, S., Rush, E., Joy, M., Bao, R., Wang, H., Vignali, D. A. A., Bruno, T. C., Kirkwood, J. M.
Topics: skin-cancer, immunotherapy, clinical-trials, research